SCHEMBL5513617

SCHEMBL5513617

NS(=O)(=O)c1ccccc1Cc1ccc(-c2nc(-c3ccccn3)no2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.66
CA9 Q16790 3/20 0.66
RAB9A P51151 11/20 0.55
SMN1; SMN2 Q16637 11/20 0.55
PKM P14618 9/20 0.55
TP53 P04637 9/20 0.55
ALDH1A1 P00352 5/20 0.55
MAPT P10636 5/20 0.55
TSHR P16473 4/20 0.55
KDM4E B2RXH2 2/20 0.55
LMNA P02545 2/20 0.55
KLF5 Q13887 2/20 0.55
HSD17B10 Q99714 2/20 0.55
HPGD P15428 1/20 0.55
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
NPC1 O15118 10/20 0.54
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5516883 0.85 CA9 (0.62) CA2CA9RAB9ASMN1; SMN2TP53
SCHEMBL5512930 0.84 CA9 (0.60) CA2CA9RAB9ASMN1; SMN2TP53
SCHEMBL5516103 0.82 NPC1 (0.54) CA2CA9RAB9ASMN1; SMN2PKM
SCHEMBL372585 0.76 LTA4H (0.43) CA2CA9CA12CA1
SCHEMBL5959913 0.73 PKM (0.77) CA2CA9RAB9ASMN1; SMN2PKM
SCHEMBL5510806 0.73 CA2 (0.58) CA2CA9RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5513620 0.72 CA2 (0.61) CA2CA9RAB9ASMN1; SMN2PKM
SCHEMBL5959953 0.72 PKM (1.00) CA2CA9RAB9ASMN1; SMN2PKM
SCHEMBL5521913 0.72 CA2 (0.57) CA2CA9RAB9APKMTP53
Dimethylamine SCHEMBL4192736 0.70 PKM (0.88) CA2CA9RAB9ASMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191341-A1 N-Substituted Benzene Sulfonamides ELAN PHARMACEUTICALS, INC. 2007-08-16 US disclosed
US-7208488-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2007-04-24 US disclosed
US-20050165003-A1 Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling ELAN PHARMACEUTICALS, INC. 2005-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165003-A1 Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling BACE1, PSEN1, BACE2 CA2 3100/4885CA9 2745/4885RAB9A 1351/4885
US-20070191341-A1 N-Substituted Benzene Sulfonamides PSEN1, PSEN2, BACE1 CA2 3239/4885CA9 3047/4885RAB9A 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.